The Effect of Methylselenocysteine and Sodium Selenite Treatment on microRNA Expression in Liver Cancer Cell Lines.


Journal

Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 12 06 2020
accepted: 30 06 2020
pubmed: 14 7 2020
medline: 13 7 2021
entrez: 14 7 2020
Statut: ppublish

Résumé

The unique character of selenium compounds, including sodium selenite and Se-methylselenocysteine (MSC), is that they exert cytotoxic effects on neoplastic cells, providing a great potential for treating cancer cells being highly resistant to cytostatic drugs. However, selenium treatment may affect microRNA (miRNA) expression as the pattern of circulating miRNAs changed in a placebo-controlled selenium supplement study. This necessitates exploring possible changes in the expression profiles of miRNAs. For this, miRNAs being critical for liver function were selected and their expression was measured in hepatocellular carcinoma (HLE and HLF) and cholangiocarcinoma cell lines (TFK-1 and HuH-28) using individual TaqMan MicroRNA Assays following selenite or MSC treatments. For establishing tolerable concentrations, IC

Identifiants

pubmed: 32656599
doi: 10.1007/s12253-020-00870-8
pii: 10.1007/s12253-020-00870-8
pmc: PMC7471166
doi:

Substances chimiques

Anticarcinogenic Agents 0
Biomarkers, Tumor 0
MicroRNAs 0
Trace Elements 0
Selenocysteine 0CH9049VIS
Sodium Selenite HIW548RQ3W
selenomethylselenocysteine TWK220499Z

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2669-2681

Subventions

Organisme : Hungarian Scientific Research Fund
ID : OTKA 128881
Organisme : Hungarian Scientific Research Fund
ID : NVKP_16_1-2016-0004
Organisme : Semmelweis Egyetem
ID : EFOP-3.6.3-VEKOP-16-2017-00009

Références

J Biol Chem. 2007 Mar 23;282(12):8759-67
pubmed: 17261587
PLoS One. 2017 Apr 27;12(4):e0174880
pubmed: 28448590
Chem Res Toxicol. 2001 Aug;14(8):996-1005
pubmed: 11511173
Int J Oncol. 2017 Feb;50(2):345-355
pubmed: 28000852
Biochemistry. 1968 Aug;7(8):2898-905
pubmed: 5666757
Biomed Pharmacother. 2016 Dec;84:1113-1118
pubmed: 27780140
Front Oncol. 2018 Dec 03;8:569
pubmed: 30560088
Cell. 1993 Dec 3;75(5):855-62
pubmed: 8252622
Metallomics. 2010 Feb;2(2):167-73
pubmed: 21069149
Cancer Manag Res. 2019 Dec 10;11:10327-10335
pubmed: 31849522
World J Gastroenterol. 2009 Apr 14;15(14):1665-72
pubmed: 19360909
Immunol Rev. 2013 May;253(1):167-84
pubmed: 23550646
Tumour Biol. 2018 May;40(5):1010428318773675
pubmed: 29775159
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087
J Clin Invest. 2012 Aug;122(8):2884-97
pubmed: 22820290
J Exp Clin Cancer Res. 2020 May 27;39(1):95
pubmed: 32460897
Dig Liver Dis. 2019 May;51(5):621-631
pubmed: 30744930
Amino Acids. 2011 Jun;41(1):29-41
pubmed: 20383543
Carcinogenesis. 2009 Aug;30(8):1416-23
pubmed: 19528666
JAMA. 1996 Dec 25;276(24):1957-63
pubmed: 8971064
Cancer Prev Res (Phila). 2011 Nov;4(11):1938-44
pubmed: 21846796
Front Med (Lausanne). 2020 Jan 31;7:7
pubmed: 32083086
Am J Pathol. 2017 Mar;187(3):570-580
pubmed: 28087162
Cell. 1993 Dec 3;75(5):843-54
pubmed: 8252621
Antioxid Redox Signal. 2010 Apr 1;12(7):867-80
pubmed: 19769465
Front Physiol. 2019 Jan 24;9:1918
pubmed: 30733684
Oncol Lett. 2012 Sep;4(3):483-488
pubmed: 23741247
J Nutr. 2009 Sep;139(9):1613-8
pubmed: 19625696
Chem Soc Rev. 2013 Dec 7;42(23):8870-94
pubmed: 24030774
Exp Ther Med. 2017 Jun;13(6):2667-2674
pubmed: 28587328
Genes Dis. 2017 Dec 06;4(4):215-221
pubmed: 30258925
Cancer Prev Res (Phila). 2009 Jul;2(7):683-93
pubmed: 19584079
Nutrients. 2015 Jun 19;7(6):4978-94
pubmed: 26102212
Biol Trace Elem Res. 2019 Jun;189(2):395-404
pubmed: 30187284
J Biol Chem. 1986 Nov 25;261(33):15529-37
pubmed: 3782077
Oncotarget. 2017 Apr 18;8(16):26312-26322
pubmed: 28412747
Xenobiotica. 1993 Jul;23(7):731-45
pubmed: 8237056
Physiology (Bethesda). 2006 Oct;21:307-15
pubmed: 16990451
Cancer Manag Res. 2020 Feb 12;12:1079-1088
pubmed: 32104088
Nutrients. 2015 May 13;7(5):3536-56
pubmed: 25984742
J Pathol. 2019 Nov;249(3):395-408
pubmed: 31301177
J Hepatol. 2008 Apr;48(4):648-56
pubmed: 18291553

Auteurs

Gábor Lendvai (G)

2nd Department of Pathology, Semmelweis University, Ulloi 93, Budapest, H-1091, Hungary.

Tímea Szekerczés (T)

2nd Department of Pathology, Semmelweis University, Ulloi 93, Budapest, H-1091, Hungary.

Endre Kontsek (E)

2nd Department of Pathology, Semmelweis University, Ulloi 93, Budapest, H-1091, Hungary.

Arun Selvam (A)

Division of Pathology, F46, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-14186, Stockholm, Sweden.

Attila Szakos (A)

Division of Pathology, F46, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-14186, Stockholm, Sweden.

Zsuzsa Schaff (Z)

2nd Department of Pathology, Semmelweis University, Ulloi 93, Budapest, H-1091, Hungary.

Mikael Björnstedt (M)

Division of Pathology, F46, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-14186, Stockholm, Sweden.

András Kiss (A)

2nd Department of Pathology, Semmelweis University, Ulloi 93, Budapest, H-1091, Hungary. kiss.andras@med.semmelweis-univ.hu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH